Received Mar 19, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | AMVBO44A | — |
liquid portion of Menveo was administered; liquid portion of Menveo was administered; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate preparation of medication in a 6-month-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVBO44A, expiry date 31-JUL-2025) for prophylaxis. Concurrent medical conditions included sickle cell disease. On 07-MAR-2025, the patient received Menveo. On 07-MAR-2025, an unknown time after receiving Menveo, the patient experienced inappropriate preparation of medication (Verbatim: liquid portion of Menveo was administered) and inappropriate dose of vaccine administered (Verbatim: liquid portion of Menveo was administered). The outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 11-MAR-2025 The nurse called to report that a patient received only the liquid portion of Menveo vaccine, which led to an inappropriate preparation of medication and inappropriate dose of vaccine administered. The patient was getting this vaccine because they have a high-risk medical condition. The vaccine administration facility was the same as primary reporter.
Sickle cell disease